BriaCell Therapeutics Corp.
BCTX
$3.62
-$0.0292-0.80%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.64% | -47.75% | -9.88% | 13.44% | -21.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.40% | -25.15% | 62.58% | 119.10% | 57.37% |
| Operating Income | 39.40% | 25.15% | -62.58% | -119.10% | -57.37% |
| Income Before Tax | -197.83% | 48.37% | 134.57% | 4.61% | 638.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -197.83% | 48.37% | 134.57% | 4.61% | 638.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -36.53% | -- | -- | -- | -- |
| Net Income | -196.68% | 49.80% | 135.05% | 4.94% | 642.39% |
| EBIT | 39.40% | 25.15% | -62.58% | -119.10% | -57.37% |
| EBITDA | 39.69% | 26.05% | -62.62% | -119.20% | -57.41% |
| EPS Basic | -158.00% | 55.30% | 134.04% | 7.71% | 626.64% |
| Normalized Basic EPS | -157.57% | 56.06% | 134.33% | 7.88% | 628.89% |
| EPS Diluted | 55.70% | 53.73% | 133.56% | 7.79% | -596.41% |
| Normalized Diluted EPS | -160.07% | 56.06% | 134.33% | 7.88% | 606.90% |
| Average Basic Shares Outstanding | 66.70% | 12.25% | 2.99% | 2.99% | 2.99% |
| Average Diluted Shares Outstanding | 59.77% | 12.25% | 2.99% | 2.99% | 7.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
